CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 38 enrolled
Drug / intervention
Oxycodone Tamper Resistant +1 moredrug
Likely dose
Oxycodone Tamper Resistant 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03398278
NCT03398278Phase 1Completed

An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fasted State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 40 mg and OXYCONTIN® Tablet 40 mg in Chinese Subjects With Chronic Pain

Mundipharma (China) Pharmaceutical Co. Ltd·interventional·Posted Jan 12, 2018·Updated Jan 31, 2020

In Brief

A Phase 1 clinical trial evaluating Oxycodone Tamper Resistant and OXYCONTIN® for Chronic Pain. Completed, enrolled 38 participants across 1 site.

Detailed Summary

This is an open-label, single dose, randomised, cross-over study to confirm the bioequivalence (BE) of OTR tablet 40 mg and OXYCONTIN tablet 40 mg in a fasted state in Chinese subjects with chronic pain

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJan 12, 2018
Enrollment StartJun 30, 2017
Primary CompletionOct 15, 2017
Study CompletionMar 20, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.5 years ago

Interventions

Oxycodone Tamper Resistantdrug

Orally taking Oxycodone Tamper Resistant 40mg in fast state

OXYCONTIN®drug

Orally taking OXYCONTIN® 40mg in fast state